Novartis returned to reinvest in digital medicine developer Pear Therapeutics as part of a Temasek-led round that took its overall funding to more than $134m.

The series A funding will help UMass-founded genetic disease therapy developer Apic Bio progress targeted drugs for ALS and Alpha-1 antitrypsin deficiency.

Half a year after raising $500m in a TUS Holdings-backed series B round, the electric car developer is seeking another $500m before it floats.

Access Industries and SIG participated in a series C round that came three months after the auto parts marketplace raised $20m in series B funding.

SenseTime has helped the autonomous driving software developer expand a series A round already featuring Alliance Ventures and Johnson Electric.

Celgene and Evotec both invested in Exscientia, as the automated drug discovery services provider added Roche to its roster of development partners.

Big data technology developer GeoSpock more than doubled its overall funding to $24.5m in a $12.8m round co-led by Mitsui Fudosan.

Biontech, a spinout of Johannes Gutenberg University Mainz, has received $91.5m in funding as part of the extension of a deal to develop a cancer immunotherapy candidate with Sanofi.

Cambridge big data analytics spinout GeoSpock has now raised $24.5m from investors including Cambridge Innovation Capital and Parkwalk Advisors.

University of Chicago’s Polsky Center for Entrepreneurship has formed microbiome-focused Avnovum Therapeutics, BiomeSense, Covira and Oxalo Therapeutics over the past year.